Stay updated on GM T-cell Therapy in AML/BPDCN Clinical Trial

Sign up to get notified when there's something new on the GM T-cell Therapy in AML/BPDCN Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the GM T-cell Therapy in AML/BPDCN Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a modification in the dose of genetically modified T-cells being administered to patients with relapsed or refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm after lymphodepleting chemotherapy.
    Difference
    0.1%
    Check dated 2024-06-06T14:40:29.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of the eligibility criteria for participation in the study.
    Difference
    57%
    Check dated 2024-05-22T21:33:20.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:52:26.000Z thumbnail image

Stay in the know with updates to GM T-cell Therapy in AML/BPDCN Clinical Trial

Enter your email address, and we'll notify you when there's something new on the GM T-cell Therapy in AML/BPDCN Clinical Trial page.